Novo Nordisk has launched its hugely popular weight-loss drug Wegovy in Thailand, an executive of the Danish drugmaker's ...

Todd Engel claims Ozempic caused his blindness. Lawsuit says Novo Nordisk failed to warn of rare vision risks.

Novo Nordisk scored a legal win against compounders of its blockbuster GLP-1 drugs. But it may not end the copycats.

Novo Nordisk has launched its popular weight-loss drug Wegovy in Thailand, marking its first entry into the Southeast Asian ...

Enrico Canal Bruland, vice president and general manager of Novo's Thai subsidiary, told Reuters that the firm received approval from the Thai FDA in 2023.

On Thursday, Reuters reported weak U.S. prescription data is contributing to investor concerns that Novo Nordisk is no longer ...

Since launching its wildly popular weight-loss drug Wegovy in 2021, Novo Nordisk has raised its annual sales guidance several ...

The court ruled in favor of Novo Nordisk and the FDA, rejecting a compounding pharmacy group's attempt to stop the FDA's ...

Patients flocked to those Ozempic, Wegovy copycats when the branded drugs were in short supply, or if they didn’t have ...

A federal judge refused to allow drug compounders to keep making copycats of Novo Nordisk A/S’s weight loss drug while a ...

Novo Nordisk remains financially strong, but pricing pressures and CagriSema challenges limit near-term upside. Find out why ...

Novo Nordisk (NYSE:NVO) stock has experienced a significant decline, dropping 35% from over $90 in early March to around $58 ...